Advancement in biomarker based effective diagnosis of neonatal sepsis

Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):476-490. doi: 10.1080/21691401.2023.2252016.

Abstract

Neonatal sepsis is considered as alarming medical emergency and becomes the common global reason of neonatal mortality. Non-specific symptoms and limitations of conventional diagnostic methods for neonatal sepsis mandate fast and reliable method to diagnose disease for point of care application. Recently, disease specific biomarkers have gained interest for rapid diagnosis that led to the development of electrochemical biosensor with enhanced specificity, sensitivity, cost-effectiveness and user-friendliness. Other than conventional biomarker C-reactive protein to diagnose neonatal sepsis, several potential biomarkers including Procalcitonin (PCT), Serum amyloid A (SAA) and other candidates are extensively investigated. The present review provides insights on advancements and diagnostic abilities of protein and nucleotide based biomarkers with their incorporation in developing electrochemical biosensors by employing novel fabrication strategies. This review provides an overview of most promising biomarker and its capability for neonatal sepsis diagnosis to fulfil future demand to develop electrochemical biosensor for point-of-care applications.

Keywords: Neonatal sepsis; biomarker; diagnosis; electrochemical biosensor; nanomaterials.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Infant, Newborn
  • Neonatal Sepsis* / diagnosis
  • Point-of-Care Systems

Substances

  • Biomarkers